Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.54 |
| ▸ | HTR2A | P28223 | 10/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.51 |
| ▸ | NPY1R | P25929 | 1/20 | 0.50 |
| ▸ | NPY2R | P49146 | 1/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957684 | 0.86 | LMNA (0.56) | SLC6A4HTR2AKCNH2NPY1RNPY2R | |
| SCHEMBL22957846 | 0.85 | NPY1R (0.70) | KCNH2NPY1RNPY2RNTRK1RECQL | |
| SCHEMBL24783619 | 0.84 | SLC6A4 (0.52) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL24180131 | 0.83 | PDE4A (0.44) | NPY1RNPY2RCARM1PRMT1PDE4A | |
| SCHEMBL22957689 | 0.81 | CARM1 (0.59) | SLC6A4HTR2AKCNH2NPY1RNPY2R | |
| SCHEMBL22957878 | 0.81 | NPY1R (0.56) | SLC6A4HTR2AKCNH2NPY1RNPY2R | |
| Hydrochloric Acid SCHEMBL7567150 | 0.81 | NPY1R (0.52) | NPY1RNPY2RCARM1PRMT1RECQL | |
| SCHEMBL20472386 | 0.80 | CSNK2A1 (0.51) | SLC6A4NPY1RNPY2RCARM1PRMT1 | |
| SCHEMBL22957842 | 0.80 | CARM1 (0.61) | SLC6A4HTR2ANPY1RNPY2RCARM1 | |
| SCHEMBL29786553 | 0.80 | CSNK2A1 (0.51) | SLC6A4NPY1RNPY2RCARM1PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3849968-B1 | 1H-INDAZOLE CARBOXAMIDES AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS (RIPK1) | BRISTOL MYERS SQUIBB CO (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3943488-A1 | SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2022-01-26 | — | — | EP | disclosed |
| EP-3580220-B1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-11-17 | — | — | EP | disclosed |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | SLC6A4 3049/4885HTR2A 2314/4885KCNH2 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.